USP and Public Policy

usp public policy
Left
usp public policy

Refine Your Search

All Results
USP Comments to Congressional Request for Information (RFI) regarding policy solutions to secure and enhance domestic medical supply chains. Submitted on October 4, 2024.  Learn More
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024) Learn More
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024. Learn More
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience; Published 2024 Learn More
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical… Learn More